Page 156 - rcv31n3.vp

Prevención cardiovascular en el diabético Revista Uruguaya de Cardiología
Washington Vignolo, Bernardo Layerle Volumen 31 | nº 3 | Diciembre 2016

invited experts). Developed with the special contri- 48. Cooper-DeHoff RM, Gong Y, Handberg EM,
bution of the European Association for Cardiovascu- Bavry AA, Denardo SJ, Brakis GL, et al. Tight
lar Prevention & Rehabilitation (EACPR). Eur blood pressure control and cardiovascular outcomes
Heart J. 2016 Aug 1;37(29):2315-81. doi:10.1093/ among hypertensive patients with diabetes and coro-
eurheartj/ehw106. nary artery disease. JAMA. 2010 Jul 7;304(1):61-8.
doi:10.1001/jama.2010.884.
39. Capodanno D, Angiolillo DJ. Aspirin for primary
cardiovascular risk prevention and beyond in diabetes 49. Beckett NS, Peters R, Fletcher AE, Staessen JA,
mellitus. Circulation. 2016 Oct 11;134(15): 1579-94. LiuL,DumitrascuD,etal. Treatment of hyperten-
doi:10.1161/ CIRCULATIONAHA.116.023164. sion in patients 80 years of age or older. N Engl J Med.
2008 May 1;358(18):1887-98.
40. Antithrombotic Trialists’ Collaboration. Colla-
doi:10.1056/NEJMoa0801369.
borative meta-analysis of randomised trials of anti-
platelet therapy for prevention of death, myocardial 50. Hansson L, Zanchetti A, Carruthers SG,
infarction, and stroke in high risk patients. BMJ. Dalhöf B, Elmfeldt D, Julius S, et al. Effects of
2002 Jan 12 [citado 2016 May 2];324(7329):71-86. intensive blood-pressure lowering and low-dose aspi-
Disponible en: http://www.ncbi.nlm.nih.gov/pub- rin in patients with hypertension?: principal results
med/11786451. of the Hypertension Optimal Treatment ( HOT ) ran-
domised trial. HOT Study Group. Lancet. 1998 Jun
41. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA,
13;351(9118):1755-62.
Hacke W, Topol EJ. Amplified benefit of clopido-
grel versus aspirin in patients with diabetes mellitus. 51. Reboldi G, Gentile G, Angeli F, Ambrosio G,
Am J Cardiol. 2002 Set 15 [citado 2016 Abr Mancia G, Verdecchia P. Effects of intensive
26];90(6):625-8. Disponible en: http://www.ncbi.nlm. blood pressure reduction on myocardial infarction
nih.gov/pubmed/12231089. and stroke in diabetes: a meta-analysis in 73,913 pa-
tients. J Hypertens. 2011 Jul;29(7):1253-69.
42. Capodanno D, Patel A, Dharmashankar K, Fe-
doi:10.1097/HJH.0b013e3283469976.
rreiro JS, Ueno M, Kodali M, et al. Pharmacodyna-
mic effects of different aspirin dosing regimens in type 52. Bangalore S, Kumar S, Lobach I, Messerli FH.
2 diabetes mellitus patients with coronary artery disea- Blood pressure targets in subjects with type 2 diabe-
se. Circ Cardiovasc Interv. 2011 Apr 19;4(2):180-7. tes mellitus/impaired fasting glucose: observations
doi:10.1161/CIRCINTERVENTIONS.110.960187. from traditional and bayesian random-effects
meta-analyses of randomized trials. Circulation.
43. Dillinger J-G, Drissa A, Sideris G, Bal dit Sollier
2011 Jun 21;123(24):2799-810.
C, VoicuS,Manzo SilbermanS,etal. Biological ef-
doi:10.1161/CIRCULATIONAHA.110.016337.
ficacy of twice daily aspirin in type 2 diabetic patients
with coronary artery disease. Am Heart J. 2012 53. Emdin CA, Rahimi K, Neal B, Callender T, Per-
Oct;164(4):600-6.e1. doi:10.1016/j.ahj.2012.06.008. kovic V, Patel A, et al. Blood pressure lowering in
type 2 diabetes. A systematic review anda
44. Addad F, Chakroun T, Elalamy I, Abderazek F,
meta-analysis. JAMA. 2015 Feb 10;313(6):603-15.
Chouchene S, Dridi Z, et al. Antiplatelet effect of
doi:10.1001/jama.2014.18574.
once- or twice-daily aspirin dosage in stable coronary ar-
tery disease patients with diabetes. Int J Hematol. 2010 54. Whelton PK, Barzilay J, Cushman WC, Davis
Sep;92(2):296-301. doi:10.1007/s12185-010-0652-3. BR, Ilamathi E, Costis JB, et al. Clinical outco-
mes in antihypertensive treatment of type 2 diabetes,
45. McBrien K, Rabi DM, Campbell N, Barnieh L,
impaired fasting glucose concentration, and nor-
Clement F, Hemmelgarn BR, et al. Intensive and
moglycemia: Antihypertensive and Lipid-Lowering
standard blood pressure targets in patients with type 2
Treatment to Prevent Heart Attack Trial
diabetes mellitus. Systematic review and meta-analy-
(ALLHAT). Arch Intern Med. 2005 Jun
sis. Arch Intern Med. 2012 Sep 24;172(17):1296-303.
27;165(12):1401-09.
doi:10.1001/archinternmed.2012.3147.
doi:10.1001/archinte.165.12.1401.
46. UK Prospective Diabetes Study Group. Tight
55. Dahlöf B, Sever PS, Poulter NR, Wedel H, Bee-
blood pressure control and risk of macrovascular and
vers DG, Caulfield M, et al; for the ASCOT in-
microvascular complications in type 2 diabetes:
vestigators. Prevention of cardiovascular events
UKPDS 38. BMJ. 1998 Sep 12 [ 2016 Abr
with an antihypertensive regimen of amlodipine ad-
26];317(7160):703-13. Disponible en: http://www.
ding perindopril as required versus atenolol adding
ncbi.nlm.nih.gov/pubmed/9732337.
bendroflumethiazide as required, in the Anglo-Scan-
47. ACCORD Study Group, Cushman WC, Evans dinavian Cardiac Outcomes Trial-Blood Pressure Lo-
GW, Byngton RP, Goff DC Jr, Grimm RH Jr, Cut- wering Arm (ASCOT-BPLA): a muticentre randomi-
ler JA, et al. Effects of intensive blood-pressure con- sed controlled trial. Lancet. 2005 Sep 10;366
trol in type 2 diabetes mellitus. N Engl J Med. 2010 Apr (9489):895-906.
29;362(17):1575-85. doi:10.1056/NEJMoa1001286. doi:10.1016/S0140-6736(05)67185-1.
500